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Background: Contraception is important for women who are postpartum, including those who are breastfeeding. Use of combined hormonal
contraceptives (CHCs) may affect breastfeeding performance and infant health outcomes.
Objective: The objective was to identify evidence examining clinical outcomes for breastfeeding and infant health among breastfeeding
women using CHCs compared to nonusers.
Search strategy: We searched the PubMed database for all articles published from database inception through September 30, 2014.
Selection criteria: We included primary research studies that compared breastfeeding women using CHCs with breastfeeding women using
nonhormonal or no contraception, or compared breastfeeding women initiating combined hormonal contraception at early versus later times
postpartum. Breastfeeding outcomes of interest included duration, rate of exclusive breastfeeding and timing of supplementation. Infant
outcomes of interest included growth, health and development.
Results: Fifteen articles describing 13 studies met inclusion criteria for this review. Studies ranged from poor to fair methodological quality
and demonstrated inconsistent effects of combined oral contraceptives (COCs) on breastfeeding performance with COC initiation before or
after 6 weeks postpartum; some studies demonstrated greater supplementation and decreased breastfeeding continuation among COC users
compared with nonusers, and others demonstrated no effect. For infant outcomes, some studies found decreases in infant weight gain for
COC users compared with nonusers when COCs were initiated at b6 weeks postpartum, while other studies found no effect. None of the
studies found an effect on infant weight gain when COCs were started after 6 weeks postpartum, and no studies found an effect on other
infant health outcomes regardless of time of COC initiation.
Conclusion: Limited evidence of poor to fair quality demonstrates an inconsistent impact of COCs on breastfeeding duration and success.
The evidence also demonstrated conflicting results on whether early initiation of COCs affects infant outcomes but generally found no
negative impact on infant outcomes with later initiation of COCs. The body of evidence is limited by older studies using different
formulations and doses of estrogen and poor methodologic quality. Given the significant limitations of this body of evidence, the importance
of contraception for postpartum women and the theoretical concerns that have been raised about the use of combined hormonal contraception
by women who are breastfeeding, rigorous studies examining these issues are needed. In addition, postpartum women should be counseled
about the full range of safe alternative contraceptive methods, particularly during the first 6 weeks postpartum when the risk of venous
thromboembolism is highest and use of estrogen may exacerbate this risk.
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Initiation of contraception during the postpartum period is
important to prevent unintended pregnancy and short birth
intervals, which can lead to negative health outcomes for
mother and infant [1,2]. For women who are breastfeeding,
the lactational amenorrhea method can be an effective
contraceptive method but is only effective for six months, or
less if menstrual bleeding resumes or supplemental feedings
are introduced [3]. Therefore, use of contraception even
among breastfeeding women is critical to prevent early
repeat pregnancy. Combined hormonal contraceptives
(CHCs) play an important role in the contraceptive method
mix, as many women prefer their familiarity and ease of use,
immediate return to fertility when discontinued and
effectiveness [4]. However, concern has been raised over
possible effects of CHCs on breastfeeding performance and
infant health.
Breastfeeding has important well-established health
benefits for both mother and infant, and these benefits can
be maximized with at least 6 months of exclusive
breastfeeding [5]. Therefore, anything that potentially
interferes with breastfeeding is of concern. Two important
areas of consideration for potential impact of medications
include effects on breastfeeding and effects on the infant. A
Cochrane systematic review that attempted to determine
the effect of hormonal contraceptives on breastfeeding
concluded that the existing randomized controlled trials
(RCTs) do not sufficiently establish an effect of hormonal
contraception on milk quality or quantity [6]. Some studies
have demonstrated that levels of hormones absorbed by the
infant are fairly low [7]; however, it is still unclear what effect
exogenous hormones have on infant growth and development.
This systematic review examines the safety of CHC use
among breastfeeding women and updates the previous review
conducted for the World Health Organization (WHO), as part
of the process of updating the Medical Eligibility Criteria for
Contraceptive Use (MEC) [8]. The previous review concluded
that the evidencewas inconsistent onwhether COCsnegatively
impacted breastfeeding duration and success and that the
evidence largely did not shownegative effects on infant growth
and development. However, the review also concluded that the
body of evidence was very limited given the poor methodo-
logic quality. Therefore, we have updated the previous review
with additional evidence in preparation for the forthcoming
update of the WHO MEC [9]. Specifically, the review
examines the effects of CHC use on clinical outcomes such
as breastfeeding duration, frequency, initiation of supplemental
feeding, weaning and infant growth, and health and develop-
ment, and examines outcomes by timing of CHC initiation.2. Materials and methods
We assessed two specific questions for this review:
(a) Do CHCs initiated by breastfeeding women at b6 weeksor N6 weeks postpartum have negative effects on breast-
feeding outcomes or infant outcomes compared with no
contraception or nonhormonal contraception? (b) Do CHCs
initiated by breastfeeding women at b6 weeks postpartum
have negative effects on breastfeeding outcomes or infant
outcomes compared with initiation at N6 weeks postpartum?
We conducted this systematic review according to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guidelines [10].
2.1. Literature search
We searched the PubMed database for all relevant articles
published from database inception through September 30,
2014, using the following search strategy:(((((((((("Contraceptives, Oral"[Mesh]) OR "oral contracep-
tives")) OR oral contracept*))) OR ("OrthoEvra"[Supplementary
Concept] OR ortho evra OR "contraceptive patch" OR
"transdermal patch"))OR ("NuvaRing"[SupplementaryConcept]
OR nuvaring OR "vaginal ring")) OR (((once a month OR
monthly) AND inject*) AND contracept* OR cyclofemOR lunelle
OR mesigyna OR cycloprovera))) AND ((("Breast Feeding"
[Mesh] or breast feeding or breastfeeding)) OR ("Lactation"
[Mesh] or lactation)) Filter: limit to human.Articles in all languages were accepted. We also searched
reference lists of identified articles and relevant review
articles for additional citations of interest. We did not
consider unpublished studies, abstracts of conference
presentations or dissertations. We previously contacted the
author of one study to clarify study methodology [11,12].
2.2. Selection criteria
Articles were included in this review if they were primary
reports on studies of breastfeeding women using CHCs
compared with breastfeeding women using nonhormonal
contraception or no contraception. Articles were also
included if they compared women who initiated CHCs
early with women who initiated CHCs at a later time
postpartum. Study designs without a comparison group were
excluded. CHCs of interest included COCs, the combined
hormonal patch, the combined vaginal ring and combined
injectables. We also included articles that included a
comparison group of women using progestin-only contra-
ceptives but considered this indirect evidence if there was no
nonhormonal comparison group. Outcomes of interest
included breastfeeding performance and infant health
outcomes. We considered clinical breastfeeding performance
outcomes such as duration of breastfeeding, exclusivity and
timing of initiation of supplemental feedings. Studies
reported a variety of breastfeeding clinical outcomes
including percent fully breastfeeding at certain times
postpartum, percent continuing to breastfeeding at certain
times postpartum, total duration of breastfeeding (without
specifying whether full or partial breastfeeding), percent
using supplementation and age at infant supplementation.
Table 1
Evidence table for studies of clinical outcomes among breastfeeding women using CHCs.
Author, year, location,
support
Study design Population Interventions (CHC and
comparison groups only)
Outcomes Results Strengths/weaknesses Quality
grading
COCs initiated b6 weeks postpartum
Kaern [20], 1967
Denmark
Source of support
not stated
(COCs supplied by
Syntex Pharmaceuticals)
RCT N=451 breastfeeding
women after healthy
delivery
COC (0.05 mg
mestranol+1 mg
norethisterone)=233
Placebo=218
Initiated on postpartum
day 1
Breastfeeding
performance
Infant weight
Breastfeeding performance:
Supplemental feeding on day 8:
COC group: 12.3% (26/212)
Placebo group: 3.4% (7/206)
(pb.05)
Infant weight:
No significant weight change
between groups from
days 2 to 8
Strengths:
Randomized treatment
Weaknesses:
Short follow-up (8 days)
Extent of blinding
difficult to assess
Method of randomization
unclear
Level I,
poor
Gambrell [18], 1970
US military hospital,
Germany
Source of support
not stated
Prospective cohort N=174 breastfeeding
women, aged 17–44
COC (various
regimens)=83
Controls (“other
method of family
planning”)=91
Initiated on postpartum
day 5
Breastfeeding
duration
Breastfeeding performance:
54% of COC users and 59%
control group were
breastfeeding at 6 weeks
(authors state not significant)
Weaknesses:
Various COC formulations
used
Short follow-up (6 weeks)
Control group may have
included users of
progestin-only methods
Self-selected intervention
No assessment of time of
breastfeeding initiation
postpartum
No adjustment for potential
confounders including age,
parity and past lactation
duration
High loss to follow-up
(~40%) over
6 weeks among all study
women; follow-up among
breastfeeding women
not noted
Level II-2,
poor
Kamal [21], 1970
Egypt
Source of support
not stated
(newly identified)
Nonrandomized
clinical trial
N=40 breastfeeding
women ages 20–37,
delivered by cesarean
section
COC (0.1 mg
mestranol+1 mg
lynestrenol)=10
Estrogen-only (0.1 mg
ethinyl estradiol)=10
Placebo=10
POP=10 (results not
reported here)
Initiated on postpartum
day 2
Infant growth Infant growth:
Percent changes in infant
weight higher in COC
group and estrogen-only
group than control
group through 14 days
(no p value reported)
Strengths:
Double-blinded
Weaknesses:
Assignment to groups
not described
Patient selection and
inclusion/exclusion
criteria not described
Small numbers
Short follow-up (14 days)
p value for comparison of
interest not reported
Level II-1,
poor
Miller [24], 1970
USA
Partially RCT
(women who
N=100 women planning
to breastfeed at least
COC (0.08 mg
mestranol+1 mg
Breastfeeding
performance
Breastfeeding performance:
More supplemental calories
Weaknesses:
Small numbers
Level I,
poor
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Ortho Research
Foundation
requested OCs
randomized to
COC or oral
placebo)
3 months; 95 included
in analyses
norethindrone)=24
Placebo (until 6 weeks,
then COCs)=23
None=48
Initiated on postpartum
day 14 or at postpartum
week 6
Infant weight required for infants in the
COC group compared to
placebo group at weeks 4
and 5 (p values not reported)
At 12 weeks postpartum,
73% in the nonhormonal
group, 52% of COC
initiators at 6 weeks and
21% of COC initiators at
2 weeks were still
breastfeeding (p values
not reported)
Infant weight:
Infants with mothers in the
placebo group had
significantly greater weight
gain than those using
COCs at weeks 4 and 5
(p values not reported)
Values and statistical
tests not stated
Method of randomization,
allocation and blinding
not specified
No power calculation
Koetsawang [23], 1972
Thailand
Source of support
not stated
(newly identified)
Prospective cohort N=94 healthy
breastfeeding women
ages 20–39; results
reported for 60 women
who completed 16 weeks
of study
COC group 1 (0.1 mg
mestranol+1 mg
ethinodiol-diacetate)=20
COC group 2 (0.08 mg
mestranol+2 mg
chlormadinone acetate)=20
Control (no hormonals)=20
Initiated within 6 weeks
postpartum (implied)
Infant growth Infant growth:
Average weight gain per
week from weeks 6
to 16 postpartum: Group 1:
147.25 g (n=16)
Group 2: 179.84 g (n=13)
Control: 202.24 g (n=20)
(authors state significant
but p value not reported)
Weaknesses:
Included only women
with previous
breastfeeding experience
Included only male infants
with birth weight
2500–3999 g
Small numbers
Assignment to contraceptive
groups not described
Exact timing of contraceptive
initiation not stated
36% (34/94) lost to follow-up
Infant growth not reported for
all women in COC groups
p value for comparison of
interest not reported
Level II-2,
poor
Guiloff, [19], 1974
Chile
Population council,
Warner-Lambert
Research Institute
Cohort study with
historic comparison
information
N=696
Multiparous women, 16–40
Control measures of
duration of lactation
came from study
women with past
lactation history and
no hormonal or
mechanical contraceptive
use who were still
lactating at 30 days
COC group 1 (2 mg
quinestrol+5 mg
quingestanol acetate)=194
COC group 2 (2 mg
quinestrol+2.5 mg
quingestanol acetate)=81
COC group 3 (0.05 mg
ethinyl estradiol+1 mg
norethindrone)=40
COC group 4 (0.08 mg
mestranol+1.5 mg
chlormadinone)=52
POC (various regimens)=168
Length of
breastfeeding
Breastfeeding performance:
Mean length of lactation:
Group 1: 2.5 months*
Group 2: 2.5 months*
Group 3: 4.6 months
Group 4: 3.7 months*
Controls: 5.3 months
*p=.01 when compared
with controls
Weaknesses:
Retrospective information
from past lactation
durations of current study
participants was used as
historical control rather than
comparison between
contraceptive groups
Assignment or choice of
contraceptive method unclear
Level II-2,
poor
(continued on next page)
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Table 1 (continued)
Author, year, location,
support
Study design Population Interventions (CHC and
comparison groups only)
Outcomes Results Strengths/weaknesses Quality
grading
(results not reported here)
Historical controls=346
Initiated on postpartum
day 30
Croxatto [11], 1983 and
Diaz [12], 1983
Chile
International
Development Research
Center of Canada,
The Population Council
Partially RCT
(randomized for
first part of study;
also women
who requested
OCs randomized
to COC or
oral placebo)
N=330 breastfeeding,
healthy women with
normal delivery and
postpartum course
COC (0.03 mg ethinyl
estradiol+0.15 mg
LNG)=103
Placebo (injectable
and pill)=188
After 91 days, 109
used nonhormonal
methods
Copper IUD= 118
Initiated on postpartum
days 30–35
Breastfeeding
performance
Infant health
(weight, weight
gain, physical
abnormalities)
Breastfeeding performance:
COC group had significantly
lower rates of exclusive
breastfeeding at postpartum
day 91 than placebo group
(80.6% vs. 92%; pb.05).
Also significantly lower rates
at 4–10 months postpartum
(pb.025) but no difference
at 12 months.
Percent weaned at 6 months:
COC: 16.3%
Placebo: 9%
Copper IUD: 4.7%
(pb.01 for COC versus IUD)
Percent weaned at 8 months:
COC: 33.3%
Placebo: 19.8%
Copper IUD: 16.5%
(pb.05)
Percent weaned not different
between groups at 2, 4, 10
and 12 months
Infant health:
Total infant weight increase
at 6 months:
COC: 4636±765 g
Placebo: 4971±669 g
pb.05
Average weight significantly
lower for COC users, from
61 to 183 days PP,
and at 366 days PP from
the nonhormonal
users (pb.05)
Average infant weight at
366 days:
COC: 9938±592 g
Placebo: 10746±729 g
pb.025
No physical abnormalities
at 1 year of age
Strengths:
Long follow-up
Weaknesses:
Although placebos used,
women chose their allocation
to pill or injectable
No determination of reason
for weaning
Level II-1,
fair
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(breasts, genitals) in
COC group
Espey [17], 2012
USA
ACOG Contraceptive
grant and University
of New Mexico
(newly identified)
RCT N=127 women
ages 15–45, planning
to breastfeed and to use
oral contraceptives
COC (0.035 mg ethinyl
estradiol+1 mg
norethindrone)=64
POP (0.35 mg
norethindrone)=63
Initiated at 2 weeks
postpartum
Breastfeeding
performance
Infant growth
(weight, length,
head circumference)
Breastfeeding performance:
No difference in breastfeeding
continuation at 8 weeks
(64% in COC group, 63.5%
in POP group)
No difference in supplementation
at 8 weeks (percents not
reported)
No difference in breastfeeding
continuation through 6 months
Infant growth:
No difference in growth
parameters through 8 weeks
Strengths:
Randomization procedure
described
Double-blinded
Minimal amount of method
switching among women
continuing to breastfeed
at 8 weeks
Loss to follow-up similar
between groups
Weaknesses:
Small numbers
Short follow-up of infant
outcomes (8 weeks)
N20% loss to follow-up in
both groups
Level I,
fair
Indirect
COCs initiated N6 weeks postpartum
Kamal [22], 1969
Egypt
Source of support
not stated
(newly identified)
Nonrandomized
clinical trial
N=120 women COC group 1 (0.075 mg
mestranol+2.5 mg
lynestrenol)
COC group 2 (0.1 mg
mestranol+1 mg
lynestrenol)
IUD+placebo
POC (results not
reported here)
Deladroxate (10 mg
estradiol enanthate+150 mg
dihydroxyprogesterone
acetophenide) (results not
reported here)
Numbers in each group
not specified
Initiated 6–10 weeks
postpartum
Breastfeeding
performance
Infant weight
Breastfeeding performance:
Average age of infant at
supplementation:
Group 1: 13.8 weeks
Group 2: 11.6 weeks
Placebo: 15.0 weeks
(no p value reported)
Infant weight:
Mean infant weight at
32 weeks postpartum
lower in group 1
and higher in group 2,
compared with placebo.
Authors state no
differences in growth
curves (exact numbers
and p values not reported).
Strengths:
Double-blinded
Weaknesses:
Assignment to groups
not described
Numbers of women in
each group and retained in
study not reported
p value for comparisons of
interest not reported
Level II-1,
poor
Peralta [26], 1983
Chile
International
Development Research
Center of Canada,
The Population Council
Prospective cohort N=141 fully
breastfeeding,
healthy women
with healthy
infants
COC (0.03 mg ethinyl
estradiol+0.15 mg
LNG)=59
Nonhormonal (spermicides,
IUD)=82
Initiated at postpartum
day 90
Breastfeeding
performance
Infant weight
Breastfeeding performance:
COC group had lower rates
of exclusive BF than
nonhormonal group at 4, 6,
8, 10 and 12 months
postpartum (pb.05)
No difference between groups
in rates of weaning through
12 months (p values not
reported)
Strengths:
Long follow-up
Low loss to follow-up
Weaknesses:
Treatment chosen
by participants
Included only healthy
infants
Small numbers reported
for infant outcomes
Level II-2,
fair
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Table 1 (continued)
Author, year, location,
support
Study design Population Interventions (CHC and
comparison groups only)
Outcomes Results Strengths/weaknesses Quality
grading
Infant weight:
No difference in mean infant
weight between groups
through postpartum day 366
At 4 months, COC group
infants had lower mean weight
increase than nonhormonal
group (pb.001). No other
significant differences
between groups through
6 months.
by 12 months
No adjustment for
potential confounders
WHO [15,27], 1984
and 1988
Hungary, Thailand
WHO/HRP
Partially randomized
clinical trial (women
who chose OCs
randomized to COC
or POP, other groups
chose methods)
N=341 women
ages 20–35,
prior experience
breastfeeding,
parity 2–4, after
healthy term delivery
COC (0.03 mg ethinyl
estradiol+0.15 mg
LNG)=86
Nonhormonal (barriers,
sterilization, IUD)=111
POC=144 (results not
reported here)
Initiated at 6 weeks
postpartum
Breastfeeding
performance
Infant growth
(weight, length,
ponderal index,
arm circumference,
skinfold thickness,
head circumference)
and morbidity
Breastfeeding performance:
No differences in breastfeeding
continuation between
contraceptive groups (rates
not reported)
No difference in prevalence
of supplementation through
24 weeks (p values not
reported)
Infant growth:
No differences in mean weight
or rate of growth between
contraceptive groups through
24 weeks; female
infants smaller in the control
group, compared to COC
group (16–24 weeks) at
one site
No differences in other infant
measurements through
24 weeks
No differences in episodes
of infant illness between groups
Strengths:
Multiple countries
Examined several infant
measurements and
infant illness
Power calculation reported
for changes in infant weight
Weaknesses:
Included only women with
prior breastfeeding
experience and with
healthy infants
No details of method
switching/discontinuation
Did not assess supplementation
No adjustment for potential
confounders
Follow up variable among
study groups and study sites;
58% follow-up at 24 weeks
in COC and nonhormonal
groups
Level II-1,
fair
Nilsson [25], 1986
Sweden
Source of support
not stated
Cohort, ambidirectional
Sweden
N=96 women using
COCs while
breastfeeding and
their infants, and
breastfeeding, non-OC
user controls and
their infants
COC (most containing
0.05 mg ethinyl
estradiol)=48
Non-OC users=48
Initiated at 2 months
postpartum
Breastfeeding
duration
Infant health
Breastfeeding duration:
Mean length of breastfeeding
(from postpartum records):
COC: 3.7 months
Controls: 4.6 months
(pb.05)
Infant health:
No differences in occurrence
of serious illness, performance
in school up to age 8
Strengths:
Long follow-up time (8 years)
Low loss to follow-up
Weaknesses:
Small numbers
19 used COCs for b1 month
and 21 used for 1–3 months
Retrospective collection of
breastfeeding information
Study group may have
contained progestin-only
OC users; control group
Level II-2,
fair
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or milk quantity, as measured by volume of pumped milk or
infant weight before and after feedings, were excluded. We
considered infant health outcomes such as growth (as
measured by weight, length, head circumference, arm
circumference or skin-fold thickness), health (as measured
by illness and mortality) and development.
2.3. Study quality assessment and data synthesis
We summarized the evidence using standard abstraction
forms. Two authors (N.T. and S.P.) independently assessed
the quality of each piece of evidence using the system
developed by the United States Preventive Services Task
Force [13,14]. Summary odds ratios were not calculated
given the heterogeneity of contraceptive initiation, results
and nonquantifiable outcomes reported. Results were
summarized and reported by timing of contraception
initiation (b6 weeks postpartum and N6 weeks postpartum)
and outcome (breastfeeding and infant health).3. Results
Our search identified 925 articles, from which 15 primary
research articles describing 13 studies met our inclusion
criteria for this review (Fig. 1 and Table 1) [11,12,15–28].
Of these articles, 10 [11,12,15,18–20,24–27] were described
in a previous review [8], 3 were newly identified for this
review but originally published before 1973, and 2 were
published since the last review [16,17,21–23]. All included
articles reported on women using COCs. No articles were
identified that reported on women using other CHCs. One
article provided indirect evidence only, as the comparison
group was women using progestin-only pills (POPs) [17].
Excluded articles most frequently reported only outcomes
of milk composition or volume without including clinically
relevant outcomes. Several additional articles were excluded
because the type of oral contraceptive (combined or
progestogen-only) was not specified, no comparison group
was included, timing of initiation of contraception or
measurement of outcomes was not stated, or the methods
did not provide enough information to determine if inclusion
criteria were met [29–37]. One article was excluded [38]
because it was a duplicate of two more comprehensive
English-language publications [12,26] of the same study.
Another article was excluded [28] because it was a subgroup
report from the WHO study, the results of which were
already included in this review [15,27].
3.1. COCs initiated at b6 weeks postpartum
3.1.1. Breastfeeding performance
We identified seven articles describing six studies that
examined women who initiated COCs at b6 weeks
postpartum and reported on breastfeeding performance
(Table 1) [11,12,17–20,24]. Studies included one RCT,
four partially randomized trials or cohort studies and one
270 N.K. Tepper et al. / Contraception 94 (2016) 262–274RCT that provides indirect evidence. Four of the studies
were conducted prior to 1973 and evaluated older formula-
tions of COCs [18–20,24]. All of the studies were included
in the previous review, with the exception of the RCT that
provides indirect evidence.
A poor-quality RCT conducted in Denmark investigated
the use of COCs (containing 0.05 mg mestranol) versus
placebo initiated on postpartum day 1 in 451 breastfeeding
mothers of healthy infants [20]. By postpartum day 8,
significantly more women in the COC group initiated
supplemental feeding for their infants than those in the
placebo group (12.3% versus 3.4%; pb.05).
A poor-quality, US-based, partially randomized trial
compared women who chose not to use hormonal contracep-
tion (n=50) with women who chose to initiate COCs (n=50)
[24]. Randomization was partial because women choosing
COCs were randomized to initiate use of COCs (containing
0.08 mg mestranol, n=25) or placebo (n= 25) at 2 weeks
postpartum. At 6 weeks postpartum, women on placebo
switched toCOCs.Womenwho initiatedCOCs at 2weeks had
higher supplemental calories given to their infants at 4 and
5 weeks postpartum compared with the placebo group
(p values not reported). This study additionally provided
some information on early comparedwith later COC initiation.
By 12 weeks, the percentages of women still breastfeeding
were 73% in the nonhormonal group, 52% among those
initiating COCs at 6 weeks and 21% among those initiating
COCs at 2 weeks (p values not reported).
A fair-quality partially randomized trial, in which random-
ization was performed for the first portion of the study,
examined 291 women after a normal delivery in Chile [11,12].
Thirty to 35 days postpartum, COCs (containing 0.03 mg
ethinyl estradiol), placebo (until 90 days postpartum when
nonhormonal methods were started) or the copper intrauterine
device (IUD) was initiated in 103, 188 and 118 women,
respectively, either randomly or according to the women'sFig. 1. Systematic review of bpreference. At postpartum day 91, the percent exclusively
breastfeeding was lower in the COC group than in the placebo
group (81% versus 92%; pb.05) [12]. The percent exclusively
breastfeeding was also lower in the COC group than the
placebo and IUD groups from 4 to 10 months postpartum
(specific percents not reported, pb.025) but not at 12 months
[11]. At 6 months postpartum, there was a significantly higher
percent weaned in the COC group compared with the copper
IUD group. At 8 months postpartum, there was a significantly
higher percent weaned in the COC group compared with the
placebo and copper IUD groups. These differences did not
persist at 10 and 12 months [11].
A poor-quality prospective cohort study of 174 women
initiating various COC regimens (n=83) or some “other
method of family planning” (not further specified) (n=91) on
postpartum day 5 were followed for 6 weeks [18]. There
were no significant differences between the groups in the
percent of women still breastfeeding at 6 weeks. Another
cohort study in Chile investigated COC use among women
who initiated at 30 days postpartum [19]. The COCs used
contained 2 mg quinestrol (n=275), 0.05 mg ethinyl estradiol
(n=40) and 0.08 mg mestranol (n=52), with various
progestin components. Duration of breastfeeding was
found to be significantly shorter for the COC group than
the nonhormonal historical control group for preparations
using mestranol or quinestrol, but not in the COC
formulations with 0.05 mg of ethinyl estradiol.
One new article of fair quality was identified, which
provided indirect evidence on breastfeeding performance
outcomes because the comparison group was women using
other hormonal contraceptives [17]. In this RCT from the
United States, women were randomized to use either COCs
(0.035 mg ethinyl estradiol) (n=64) or POPs (n=63) initiated
at 2 weeks postpartum. At 8 weeks postpartum, there was no
statistically significant difference in breastfeeding continua-
tion or supplementation between the COC group and the POPreastfeeding and CHCs.
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breastfeeding continuation at 6 months postpartum (percents
not reported).
3.1.2. Infant outcomes
There were seven articles describing six studies which
examinedwomenwho initiated COCs atb6weeks postpartum
and reported on infant outcomes [11,12,17,20,21,23,24].
Three of these studies were newly identified: two were older
studies, and one was published since the previous review
[17,21,23]. As with the breastfeeding outcomes, four of these
studies were conducted before 1973 and examined older,
higher-dose COC formulations [20,21,23,24].
In the RCT from Denmark described above, no significant
differences in infant weight among infants exclusively
breastfed were noted by postpartum day 8 between women
using COCs and those using placebo [20]. In the US
partially-randomized trial described above, infants in the
placebo group gained more weight than infants in the COC
group at 4 and 5weeks postpartum, although p values were not
reported [24]. In the partially randomized study fromChile, the
average infant weight of exclusively breastfed infants was
lower in the COC group than the placebo group from 61 to 183
days and at 366 days postpartum (pb.05) [11,12]. The total
infantweight increase at 6monthswas lower in the COCgroup
than in the placebo group (4636 g versus 4971 g; pb.05) [11].
No physical manifestations of exogenous estrogen, such as
genital or breast changes, were noted in the infants in the COC
group up to 1 year postpartum [11].
One newly identified poor-quality clinical trial from Egypt
provided women after cesarean delivery with oral hormonal
contraceptives or placebo pills initiated on postpartum day 2
[21]. The study was double-blinded, but the authors did not
specify whether women were randomized. Ten women used
COCs (0.1 mg mestranol), 10 women used an estrogen-only
pill (0.1 mg ethinyl estradiol), and 10 women used placebo
pills. At 14 days postpartum, the percent increases in infant
weight were higher in the COC and estrogen-only groups
comparedwith the placebo group; however, exact percents and
p values were not reported.
One newly identified poor-quality prospective cohort
study from Thailand reported on postpartum women who
initiated COCs within 6 weeks postpartum [23]. Group 1
included 20 women using a COC with 0.1 mg of mestranol,
and group 2 included 20 women using a COC with 0.08 mg
mestranol. The control group included 20 women using no
hormonal contraceptive. The outcome of average infant
weight gain per week was only reported for 16 women in
group 1 and 13 women in group 2 versus all 20 women in the
control group. The average infant weight gain per week from
weeks 6 to 16 postpartum was lower in the COC groups
(group 1=147 g; group 2=180 g) than in the control group
(202 g); the authors state that this difference was significant,
but no p values were reported.
In the newly published RCT described above which
provided indirect evidence, there were no differences ininfant growth parameters, as measured by weight, length and
head circumference, at 8 weeks postpartum among those
whose mothers were using COCs compared with POPs [17].3.2. COCs initiated at N6 weeks postpartum
3.2.1. Breastfeeding performance
Six articles reporting on five studies examined women
initiating COCs at N6 weeks postpartum and reported on
breastfeeding performance [15,16,22,25–27]. Two of these
studies were newly identified: one was an older study, and
one was published since the previous review [16,22]. One
study was a partially randomized trial, one was a
nonrandomized trial, and three were cohort studies. Two
studies evaluated higher-dose pills [22,25], while the other
three studies examined 0.03-mg ethinyl estradiol pills.
WHOconducted a fair-quality partially randomized clinical
trial at three centers in two countries on the effect of oral
contraception, both progestin-only and combined (0.03 mg
ethinyl estradiol), initiated at 6 weeks postpartum [15,27].
Women choosing oral contraceptives were randomly assigned
to either progestin-only or combined pills (n=86 for COCs).
Women who chose IUDs, barrier methods, sterilization or
no contraception were included as nonhormonal controls
(n=111). At 24 weeks postpartum, there were no significant
differences in breastfeeding continuation (rates not reported)
or prevalence of supplementation between groups (p values
not reported) [27].
One newly identified poor quality nonrandomized clinical
trial from Egypt divided women into five groups of hormonal
and nonhormonal contraceptives initiated at 6–10 weeks
postpartum [22]. Two of the groups used COCs: group 1 used
aCOCwith 0.075mgmestranol, and group 2 used a COCwith
0.1mgmestranol. The comparison groupwas women using an
IUD (type not specified) plus placebo. The average age of the
infant at supplementation was lower in the COC groups (group
1=13.8 weeks; group 2=11.6 weeks) than in the placebo group
(15 weeks); however, p values were not reported.
One newly published fair-quality prospective cohort
study from Brazil examined 10 postpartum women who
initiated COCs (0.03 mg ethinyl estradiol) at 42 days
postpartum [16]. Compared with 10 women using copper
IUDs, women using COCs had a higher mean number of
breastfeeding episodes on 7 out of 21 days from postpartum
days 42–63 (pb.05); breastfeeding episodes were not
different on the remaining days. The duration of exclusive
breastfeeding was similar between groups at 6 months,
although the exact duration and p values were not reported.
In a fair-quality prospective cohort study from Chile,
postpartum women exclusively breastfeeding chose to
initiate either COCs (0.03 mg ethinyl estradiol, n=59) or
nonhormonal contraception (n=82) at 90 days postpartum
[26]. The COC group had lower rates of exclusive
breastfeeding than the nonhormonal group at 4, 6, 8, 10
and 12 months (pb.05). The COC group also had higher
proportions initiating supplementation at the same time
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percent weaning at 6, 8, 10 and 12 months, although p values
were not reported.
One fair-quality cohort study in Sweden examined 48
women who initiated OCs (most used COCs with 0.05 mg
ethinyl estradiol) at 2 months postpartum compared with 48
controls who did not use OCs [25]. The mean length of
breastfeeding was shorter in the COC group than in the
control group, 3.7 months versus 4.6 months (pb.05).
3.2.2. Infant outcomes
Six articles reporting on five studies examined women
initiating COCs at N6 weeks postpartum and reported on
infant outcomes [15,16,22,25–27]. Two of these studies
were newly identified: one was an older study, and one was
published since the last review [16,22].
In the newly identified study from Egypt described above,
there were no differences between groups in infant growth
curves at 32 weeks postpartum (stated by authors, but exact
numbers and p values not reported) [22]. In the newly
published study from Brazil, there were no significant
differences in infant growth, as measured by weight, height
and tibia length, at 63 days postpartum [16].
The remaining studies were included in the previous review
and also did not demonstrate any effects on infant outcomes. In
the study from Chile described above, mean infant weight did
not significantly differ betweenCOC and nonhormonal groups
through postpartum day 366. At 4months of age, meanweight
increase in the COC group was lower than the nonhormonal
group (pb.001); however, there were no differences at any
other time points through 6 months [26]. The WHO study
described above found no differences between the COC and
nonhormonal groups in infant growth (including weight,
length, ponderal index, arm circumference, triceps skinfold
thickness and head circumference), infant illness episodes or
number of days of sickness through 24 weeks [15,27]. In the
study with longest child follow-up, there were no differences
in weight gain, height increase, occurrence of serious illness or
school performance between the COC and control groups
through 8 years of follow-up [25].4. Discussion
Studies addressing possible effects of COC use on
breastfeeding success and corresponding infant health and
growth include 13 studies, published in 15 articles, 5 of which
are newly identified for this updated review. In general, results
from the new studies added to this review are consistent with
previous findings on breastfeeding performance and infant
outcomes among CHC users compared with nonusers.
Among studies examining COCs initiated at b6 weeks
postpartum, results were inconsistent regarding breastfeeding
performance. Of the previously identified studies, three
poor-quality studies and one fair-quality study found some
diminished breastfeeding outcomes among COC users, includ-ing increased proportions using supplementation and decreased
proportions continuing to breastfeed [11,12,19,20,24], while
one poor-quality study found no effect on breastfeeding
continuation at 6 weeks [18]. One newly identified, indirect
study of fair quality found no effect on supplementation or
breastfeeding continuation when compared with POPs [17].
Among studies examining COCs initiated at b6 weeks
postpartum, results were also inconsistent on infant outcomes.
Of the previously identified studies, one fair-quality study and
one poor-quality study found less weight gain in infants of COC
users compared with nonusers [11,12,24], and one poor-quality
study found no effect on weight gain [20]. Of the newly
identified studies, one poor-quality study found some effect
on weight gain [23], but one poor-quality study and one
fair-quality, indirect study found no effect [21,17].
Among studies examining COCs initiated at N6 weeks
postpartum, results were inconsistent on breastfeeding
performance. Of the previously identified articles, two
fair-quality studies showed some diminished breastfeeding
performance among COC users [25,26], and two fair-quality
studies showed no effect [15,27]. Of the newly identified
articles, one poor-quality study showed some diminished
breastfeeding among COC users [22], and one fair-quality
study did not [16]. Among studies examining COCs initiated
at N6 weeks postpartum, results were consistent with regard
to infant outcomes, with no articles finding differences in
either infant growth or health. Newly identified articles
reporting infant outcomes [16,22] were consistent with those
previously identified [15,25–27].
There are several limitations to this body of evidence.
There were only two direct-evidence randomized or partially
randomized trials, both of poor quality, and neither described
randomization procedures [20,24]. Most of the observational
studies were of poor quality and included small numbers of
women, had short follow-up times (less than 6 weeks) or had
high loss to follow-up. Several poor-quality studies included
only women with previous breastfeeding experience, and
others did not control for previous breastfeeding experience.
Many of the studies did not conduct statistical tests for
comparisons of interest and did not control for other potential
confounders. Studies used a variety of outcomes to define
“successful” breastfeeding, therefore making comparison
between studies difficult. The vast majority of articles were
published in the 1960s–1980s using higher doses and
different formulations of estrogen than currently available,
limiting the generalizablity of this body of evidence to
current formulations and delivery systems of modern CHCs.
Overall, the evidence identified by this systematic review
found inconsistent effects on clinical breastfeeding measures.
The physiology of breastfeeding is mediated by several
hormones, including estrogen, progesterone, prolactin, insulin,
thyroxin, growth hormone and cortisol [39]. Lactation is
triggered by progesterone withdrawal after delivery of the
placenta, which leads to prolactin secretion [39,40]. While this
drop in progesterone appears to be the key trigger, estrogen
withdrawal also accompanies secretory activation. Some studies
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lactation; however, these studies involved administration of
different types of estrogen at different doses and time frames
than those given for contraceptive purposes [41]. Paradoxically,
although a drop in estrogen correlates with lactation initiation,
estrogen actually stimulates prolactin release [42]. The
mechanism through which estrogen may inhibit lactation is
notwell understood butmay involve direct suppression in breast
tissue [42].
Studies have generally found that very low levels of
hormones transfer to the infant during breastfeeding [7].
While evidence is limited, studies have demonstrated that
low levels of estrogen and progestins are present in breast
milk [7,43,44]. However, there is theoretical concern that
hormone levels may be higher in the infant because the
immature liver may not metabolize effectively, the kidneys
may be inefficient at excretion and plasma-binding capacity
may be low [7]. Nonetheless, evidence identified by this
systematic review generally did not support negative clinical
consequences for infants exposed to CHCs.
Given the significant limitations of this body of evidence,
the importance of contraception for postpartumwomen and the
theoretical concerns that have been raised about the use of
combined hormonal contraception by women who are
breastfeeding, rigorous studies examining these issues are
needed. Studies should be undertaken among breastfeeding
women using modern low-dose COCs as well as the combined
hormonal patch, combined vaginal ring and combined
injectables. However, consensus is needed among researchers
on several critical issues for the design and interpretation of
new studies, including study design (i.e., which questions
are best suited for observational studies and which might
only be able to be answered with RCTs), breastfeeding and
infant outcomes (i.e., which are most important to guide
recommendations), and development of standard definitions
and measurements. Study design should include careful
consideration of intervention and comparison groups, reporting
of exact timing of contraceptive initiation and control for
important factors such as prior breastfeeding experience.
Attempt should be made to maximize generalizability of
results by considering characteristics of women who partici-
pate in such studies and by inclusion of ill or preterm infants.
Studies should follow women for at least the first few months
postpartum to truly assess any impact on breastfeeding
performance. In addition, longer-term follow-up of infants
exposed to hormones through breast milk is needed in order to
more fully understand any impacts on child development.
When considering choice of contraceptive methods, it is
important to consider the full context of the risks and benefits
and alternatives. For breastfeeding women, in addition to
potential impacts on breastfeeding and infant health, there
are additional considerations due to their postpartum status.
The increased risk of venous thromboembolism (VTE)
among postpartum women particularly in the first 6 weeks,
coupled with the increased risk of VTE with use of CHCs,
suggests that estrogen-containing contraceptive methodsmay increase the risk of VTE in postpartum women to an
unacceptable level [45–47]. Alternative methods of contra-
ception, including more effective methods such as IUDs and
implants, are safe for postpartum women, and women should
be counseled about the full range of contraceptive options [9].
In conclusion, fair- to poor-quality evidence showed
conflicting results on whether use of COCs affects
breastfeeding performance. The evidence also demonstrated
conflicting results on whether early initiation of COCs
affects infant outcomes but generally no negative impact on
infant outcomes with later initiation of COCs. The body of
evidence is limited by older studies using different
formulations and doses of estrogen and poor methodologic
quality. The information in this review was presented to an
expert review panel in March 2014 at a meeting convened by
WHO. The findings of this systematic review will be
incorporated into the forthcoming update of the WHOMEC.Acknowledgements
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